<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00373113</url>
  </required_header>
  <id_info>
    <org_study_id>A6181107</org_study_id>
    <nct_id>NCT00373113</nct_id>
  </id_info>
  <brief_title>A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine</brief_title>
  <official_title>Phase III Randomized, Multi Center Study Of Sunitinib Malate (SU 011248) Or Capecitabine In Subjects With Advanced Breast Cancer Who Failed Both A Taxane And An Anthracycline Chemotherapy Regimen Or Failed With A Taxane And For Whom Further Anthracycline Therapy Is Not Indicated</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare efficacy and safety of Sunitinib and Capecitabine in subjects with advanced breast
      cancer who failed both a taxane and an anthracycline chemotherapy regimen or failed with a
      taxane and for whom further anthracycline therapy is not indicated
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient enrollment in this trial was discontinued based on statistical assessment for
      futility. An independent Data Monitoring Committee found that even if the trial had been
      allowed to continue, treatment with single agent sunitinib would be unable to demonstrate a
      statistically significant improvement in the primary endpoint of progression-free survival
      compared with single agent capecitabine in the study population. Pfizer notified clinical
      trial investigators involved in the study and regulatory agencies of these findings on
      25Mar2009. Patients receiving sunitinib will be allowed to receive capecitabine or enter an
      extension trial if they are receiving clinical benefit from continued sunitinib therapy.
      There were no safety concerns leading to the decision to terminate the study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    See termination reason in detailed description.
  </why_stopped>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>From time of randomization to every 6 weeks thereafter through 22 months or until death</time_frame>
    <description>Time from the date of randomization to the date of the first documentation of objective tumor progression or death due to any cause, whichever occured first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Tumor Progression (TTP)</measure>
    <time_frame>From time of randomization to every 6 weeks thereafter through 22 months</time_frame>
    <description>Time from randomization to first documentation of objective tumor progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Overall Response (OR)</measure>
    <time_frame>From time of randomization to every 6 weeks thereafter through 22 months</time_frame>
    <description>OR was defined as the number of participants with confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST, Version 1.0) for at least 4 weeks, confirmed by repeat tumor assessments. CR was defined as the disappearance of all target lesions. PR was defined as a greater than or equal to (&gt;=) 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DR)</measure>
    <time_frame>From time of randomization to every 6 weeks thereafter through 22 months or death</time_frame>
    <description>Time from the first documentation of OR (CR or PR) that was subsequently confirmed to the first documentation of tumor progression or death due to any cause. CR was defined as disappearance of all target lesions. PR was defined as a &gt;= 30% decrease in sum of longest dimensions of target lesions taking as a reference baseline sum longest dimensions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Tumor Response (TTR)</measure>
    <time_frame>From time of randomization to every 6 weeks thereafter through 22 months</time_frame>
    <description>Time from randomization to the first documentation of objective tumor response (CR or PR) that was subsequently confirmed. CR was defined as disappearance of all target lesions. PR was defined as a &gt;= 30% decrease in sum of longest dimensions of target lesions taking as a reference baseline sum longest dimensions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From time of randomization until death</time_frame>
    <description>Average time from randomization to first documentation of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC QLQ-C30)</measure>
    <time_frame>From Day 1 of Cycle 1, then odd numbered cycles thereafter</time_frame>
    <description>EORTC QLQ-C30 scales: functional (physical/role/cognitive/emotional/social), symptom (fatigue/nausea/vomiting/pain), global health/QOL, cancer symptom (dyspnea/insomnia/appetite loss/constipation/diarrhea).
Feelings in past week: response range: not at all to very much, global/QOL range: very poor to excellent. Scales/single-items averaged, score 0 to 100. Higher functional/global=better functioning and symptom=greater degree of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EORTC QLQ Breast Cancer Module (BR23)</measure>
    <time_frame>From Day 1 of Cycle 1, then odd numbered cycles thereafter</time_frame>
    <description>BR23: measured disease related symptoms of dry mouth, eye pain, hair loss, hot flushes, attractiveness, future health, sexual activity, arm/shoulder pain, breast pain, swollen breast, and skin problems on the breast. Recall period: past week; response range: not at all to very much.
Scale score range: 0 to 100. Higher symptom score implied a greater degree of symptoms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">482</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1250 mg/m^2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>37.5 mg daily, continuous dosing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>1250 mg/m^2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles</description>
    <arm_group_label>A</arm_group_label>
    <other_name>xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunitinib malate</intervention_name>
    <description>37.5 mg daily, continuous dosing</description>
    <arm_group_label>B</arm_group_label>
    <other_name>sunitinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  breast adenocarcinoma

          -  prior treatment with an anthracycline and a taxane either concurrently or sequentially
             in the neoadjuvant, adjuvant and or/ advanced disease treatment settings. No more than
             1 chemotherapy regimen in the advanced setting

        Exclusion Criteria:

          -  Prior treatment with regimens of chemotherapy in the advanced/metastatic disease
             setting beyond those containing anthracyclines and taxanes or multiple anthracyclines/
             taxanes treatments.

          -  Any prior regimen with capecitabine
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bahia Blanca</city>
        <state>Prov. de Buenos Aires</state>
        <zip>B8001HXM</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Viedma</city>
        <state>Rio Negro</state>
        <zip>8500</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fé</state>
        <zip>(2000)</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1034ACO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1405BCH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cordoba</city>
        <zip>X5000AAI</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tucuman</city>
        <zip>T4000IAK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Curitiba</city>
        <state>PR</state>
        <zip>80530-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>20560-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>91350-200</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>01246-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>01509-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1233</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1756</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Stara Zagora</city>
        <zip>6000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Temuco</city>
        <state>IX Región</state>
        <zip>4810469</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bogotá</city>
        <state>Cundinamarca</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bayonne</city>
        <zip>64100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lille</city>
        <zip>59020 Cedex</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Neuilly Sur Seine</city>
        <zip>92200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nice</city>
        <zip>06100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rennes Cedex</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Jena</city>
        <zip>07743</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kiel</city>
        <zip>24103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Leer</city>
        <zip>26789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Luebeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Magdeburg</city>
        <zip>39130</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mainz</city>
        <zip>55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Meiningen</city>
        <zip>98617</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Muenchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Offenburg</city>
        <zip>77652</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kowloon</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tuen Mun</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Wan Chai,</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Navrangpura / Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380 009</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560 078</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ludhiana</city>
        <state>Punjab</state>
        <zip>141 008</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302013</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lucknow</city>
        <state>Uttar Pradesh</state>
        <zip>226003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Matsuyama-shi</city>
        <state>Ehime</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kitakyushu-City</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kita-adachi-gun</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chuo-Ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Daegu</city>
        <zip>705-717</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Incheon</city>
        <zip>400-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pusan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mexico</city>
        <state>DF</state>
        <zip>11000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Toluca</city>
        <state>Estado de Mexico</state>
        <zip>50180</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Acapulco</city>
        <state>Guerrero</state>
        <zip>39670</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Morelia</city>
        <state>Michoacan</state>
        <zip>58020</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ciudad Obregon</city>
        <state>Sonora</state>
        <zip>85000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chihuahua</city>
        <zip>31000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Puebla</city>
        <zip>72530</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lima</city>
        <zip>05127</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lima</city>
        <zip>L 27</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Quezon City</city>
        <zip>1100</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Quezon City</city>
        <zip>1102</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Quezon City</city>
        <zip>1104</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Juan City</city>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Parktown</city>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sandton</city>
        <zip>2199</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mataro</city>
        <state>Barcelona</state>
        <zip>08304</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Alcorcon</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bilbao</city>
        <state>Vizcaya</state>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gerona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Jaen</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>La Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <zip>35016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Changhua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>106</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34390</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cardiff</city>
        <state>South Wales</state>
        <zip>CF14 2TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Somerset</city>
        <zip>BA21 4AT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>India</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Singapore</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6181107&amp;StudyName=A%20Clinical%20Trial%20Comparing%20Efficacy%20And%20Safety%20Of%20Sunitinib%20And%20Capecitabine</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2006</study_first_submitted>
  <study_first_submitted_qc>September 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2006</study_first_posted>
  <results_first_submitted>October 20, 2010</results_first_submitted>
  <results_first_submitted_qc>October 20, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 18, 2010</results_first_posted>
  <last_update_submitted>June 15, 2012</last_update_submitted>
  <last_update_submitted_qc>June 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>advanced breast cancer</keyword>
  <keyword>metastatic breast cancer</keyword>
  <keyword>treatment resistant</keyword>
  <keyword>treatment failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sunitinib</title>
          <description>37.5 milligrams (mg) daily, continuous dosing</description>
        </group>
        <group group_id="P2">
          <title>Capecitabine</title>
          <description>1250 milligrams per square meter (mg/m^2) or 1000 mg/m^2 in older participants, twice daily for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="238"/>
                <participants group_id="P2" count="244"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="238"/>
                <participants group_id="P2" count="240"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="238"/>
                <participants group_id="P2" count="244"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study terminated by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Global deterioration of health status</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Objective progression or relapse</title>
              <participants_list>
                <participants group_id="P1" count="150"/>
                <participants group_id="P2" count="169"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sunitinib</title>
          <description>37.5 mg daily, continuous dosing</description>
        </group>
        <group group_id="B2">
          <title>Capecitabine</title>
          <description>1250 milligrams per square meter (mg/m^2) or 1000 mg/m^2 in older participants, twice daily for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="238"/>
            <count group_id="B2" value="244"/>
            <count group_id="B3" value="482"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18 to 44 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 to 64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="159"/>
                    <measurement group_id="B2" value="129"/>
                    <measurement group_id="B3" value="288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; = 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="238"/>
                    <measurement group_id="B2" value="244"/>
                    <measurement group_id="B3" value="482"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-Free Survival (PFS)</title>
        <description>Time from the date of randomization to the date of the first documentation of objective tumor progression or death due to any cause, whichever occured first.</description>
        <time_frame>From time of randomization to every 6 weeks thereafter through 22 months or until death</time_frame>
        <population>Intent-to-treat (ITT) population: included all participants who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib</title>
            <description>37.5 mg daily, continuous dosing</description>
          </group>
          <group group_id="O2">
            <title>Capecitabine</title>
            <description>1250 milligrams per square meter (mg/m^2) or 1000 mg/m^2 in older participants, twice daily for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival (PFS)</title>
          <description>Time from the date of randomization to the date of the first documentation of objective tumor progression or death due to any cause, whichever occured first.</description>
          <population>Intent-to-treat (ITT) population: included all participants who were randomized.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
                <count group_id="O2" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="2.4" upper_limit="4.0"/>
                    <measurement group_id="O2" value="4.2" lower_limit="3.8" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis is that PFS (median=4.2 months) for sunitinib arm equals PFS for capecitabine arm. The study was designed to have 90% power to detect statistical difference in PFS between two treatment groups assuming the hazard ratio (sunitinib/capecitabine) is 0.75 and both arms follow exponential distribution.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>2-sided log-rank test with the same set of stratification factors. The set of stratification factors included those used in the randomization except study sites.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.470</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.156</ci_lower_limit>
            <ci_upper_limit>1.869</ci_upper_limit>
            <estimate_desc>Hazard ratio was calculated by the stratified Cox proportional hazards model.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Tumor Progression (TTP)</title>
        <description>Time from randomization to first documentation of objective tumor progression.</description>
        <time_frame>From time of randomization to every 6 weeks thereafter through 22 months</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib</title>
            <description>37.5 mg daily, continuous dosing</description>
          </group>
          <group group_id="O2">
            <title>Capecitabine</title>
            <description>1250 milligrams per square meter (mg/m^2) or 1000 mg/m^2 in older participants, twice daily for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Tumor Progression (TTP)</title>
          <description>Time from randomization to first documentation of objective tumor progression.</description>
          <population>ITT population</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
                <count group_id="O2" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="2.5" upper_limit="4.0"/>
                    <measurement group_id="O2" value="4.2" lower_limit="3.8" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>2-sided log-rank test with the same set of stratification factors that was used in the randomization except study sites.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.516</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.188</ci_lower_limit>
            <ci_upper_limit>1.933</ci_upper_limit>
            <estimate_desc>Hazard ratio was calculated by the stratified Cox proportional hazards model.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Overall Response (OR)</title>
        <description>OR was defined as the number of participants with confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST, Version 1.0) for at least 4 weeks, confirmed by repeat tumor assessments. CR was defined as the disappearance of all target lesions. PR was defined as a greater than or equal to (&gt;=) 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.</description>
        <time_frame>From time of randomization to every 6 weeks thereafter through 22 months</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib</title>
            <description>37.5 mg daily, continuous dosing</description>
          </group>
          <group group_id="O2">
            <title>Capecitabine</title>
            <description>1250 milligrams per square meter (mg/m^2) or 1000 mg/m^2 in older participants, twice daily for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Overall Response (OR)</title>
          <description>OR was defined as the number of participants with confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST, Version 1.0) for at least 4 weeks, confirmed by repeat tumor assessments. CR was defined as the disappearance of all target lesions. PR was defined as a greater than or equal to (&gt;=) 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.</description>
          <population>ITT population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
                <count group_id="O2" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Objective Response Rate (ORR) (percent)</param_type>
            <param_value>11.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.6</ci_lower_limit>
            <ci_upper_limit>16.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Objective Response Rate (ORR) (percent)</param_type>
            <param_value>16.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.0</ci_lower_limit>
            <ci_upper_limit>21.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.109</p_value>
            <method>Pearson Chi-Square Test</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.049</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.2</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DR)</title>
        <description>Time from the first documentation of OR (CR or PR) that was subsequently confirmed to the first documentation of tumor progression or death due to any cause. CR was defined as disappearance of all target lesions. PR was defined as a &gt;= 30% decrease in sum of longest dimensions of target lesions taking as a reference baseline sum longest dimensions.</description>
        <time_frame>From time of randomization to every 6 weeks thereafter through 22 months or death</time_frame>
        <population>ITT population. DR was calculated for the subgroup of participants with objective response. 27 participants in the sunitinib arm and 40 participants in the capecitabine arm reported CR or PR response and were analyzed for DR.</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib</title>
            <description>37.5 mg daily, continuous dosing</description>
          </group>
          <group group_id="O2">
            <title>Capecitabine</title>
            <description>1250 milligrams per square meter (mg/m^2) or 1000 mg/m^2 in older participants, twice daily for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DR)</title>
          <description>Time from the first documentation of OR (CR or PR) that was subsequently confirmed to the first documentation of tumor progression or death due to any cause. CR was defined as disappearance of all target lesions. PR was defined as a &gt;= 30% decrease in sum of longest dimensions of target lesions taking as a reference baseline sum longest dimensions.</description>
          <population>ITT population. DR was calculated for the subgroup of participants with objective response. 27 participants in the sunitinib arm and 40 participants in the capecitabine arm reported CR or PR response and were analyzed for DR.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" lower_limit="3.1" upper_limit="8.5"/>
                    <measurement group_id="O2" value="9.3" lower_limit="5.5" upper_limit="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.037</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>2.788</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.042</ci_lower_limit>
            <ci_upper_limit>7.459</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Tumor Response (TTR)</title>
        <description>Time from randomization to the first documentation of objective tumor response (CR or PR) that was subsequently confirmed. CR was defined as disappearance of all target lesions. PR was defined as a &gt;= 30% decrease in sum of longest dimensions of target lesions taking as a reference baseline sum longest dimensions.</description>
        <time_frame>From time of randomization to every 6 weeks thereafter through 22 months</time_frame>
        <population>The study was stopped early for futility and TTR analysis was not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib</title>
            <description>37.5 mg daily, continuous dosing</description>
          </group>
          <group group_id="O2">
            <title>Capecitabine</title>
            <description>1250 milligrams per square meter (mg/m^2) or 1000 mg/m^2 in older participants, twice daily for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Tumor Response (TTR)</title>
          <description>Time from randomization to the first documentation of objective tumor response (CR or PR) that was subsequently confirmed. CR was defined as disappearance of all target lesions. PR was defined as a &gt;= 30% decrease in sum of longest dimensions of target lesions taking as a reference baseline sum longest dimensions.</description>
          <population>The study was stopped early for futility and TTR analysis was not performed.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>Average time from randomization to first documentation of death due to any cause.</description>
        <time_frame>From time of randomization until death</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib</title>
            <description>37.5 mg daily, continuous dosing</description>
          </group>
          <group group_id="O2">
            <title>Capecitabine</title>
            <description>1250 milligrams per square meter (mg/m^2) or 1000 mg/m^2 in older participants, twice daily for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Average time from randomization to first documentation of death due to any cause.</description>
          <population>ITT population</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
                <count group_id="O2" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3" lower_limit="12.0" upper_limit="24.7"/>
                    <measurement group_id="O2" value="16.9" lower_limit="14.5" upper_limit="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.219</p_value>
            <p_value_desc>2-sided log-rank test with the same set of stratification factors that were used in the randomization except study sites.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.202</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.896</ci_lower_limit>
            <ci_upper_limit>1.611</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC QLQ-C30)</title>
        <description>EORTC QLQ-C30 scales: functional (physical/role/cognitive/emotional/social), symptom (fatigue/nausea/vomiting/pain), global health/QOL, cancer symptom (dyspnea/insomnia/appetite loss/constipation/diarrhea).
Feelings in past week: response range: not at all to very much, global/QOL range: very poor to excellent. Scales/single-items averaged, score 0 to 100. Higher functional/global=better functioning and symptom=greater degree of symptoms.</description>
        <time_frame>From Day 1 of Cycle 1, then odd numbered cycles thereafter</time_frame>
        <population>The study was stopped early for futility and EORTC QLQ-C30 analysis was not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib</title>
            <description>37.5 mg daily, continuous dosing</description>
          </group>
          <group group_id="O2">
            <title>Capecitabine</title>
            <description>1250 milligrams per square meter (mg/m^2) or 1000 mg/m^2 in older participants, twice daily for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles</description>
          </group>
        </group_list>
        <measure>
          <title>European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC QLQ-C30)</title>
          <description>EORTC QLQ-C30 scales: functional (physical/role/cognitive/emotional/social), symptom (fatigue/nausea/vomiting/pain), global health/QOL, cancer symptom (dyspnea/insomnia/appetite loss/constipation/diarrhea).
Feelings in past week: response range: not at all to very much, global/QOL range: very poor to excellent. Scales/single-items averaged, score 0 to 100. Higher functional/global=better functioning and symptom=greater degree of symptoms.</description>
          <population>The study was stopped early for futility and EORTC QLQ-C30 analysis was not performed.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EORTC QLQ Breast Cancer Module (BR23)</title>
        <description>BR23: measured disease related symptoms of dry mouth, eye pain, hair loss, hot flushes, attractiveness, future health, sexual activity, arm/shoulder pain, breast pain, swollen breast, and skin problems on the breast. Recall period: past week; response range: not at all to very much.
Scale score range: 0 to 100. Higher symptom score implied a greater degree of symptoms.</description>
        <time_frame>From Day 1 of Cycle 1, then odd numbered cycles thereafter</time_frame>
        <population>The study was stopped early for futility and EORTC QLQ Cancer Module (BR23) analysis was not performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib</title>
            <description>37.5 mg daily, continuous dosing</description>
          </group>
          <group group_id="O2">
            <title>Capecitabine</title>
            <description>1250 milligrams per square meter (mg/m^2) or 1000 mg/m^2 in older participants, twice daily for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles</description>
          </group>
        </group_list>
        <measure>
          <title>EORTC QLQ Breast Cancer Module (BR23)</title>
          <description>BR23: measured disease related symptoms of dry mouth, eye pain, hair loss, hot flushes, attractiveness, future health, sexual activity, arm/shoulder pain, breast pain, swollen breast, and skin problems on the breast. Recall period: past week; response range: not at all to very much.
Scale score range: 0 to 100. Higher symptom score implied a greater degree of symptoms.</description>
          <population>The study was stopped early for futility and EORTC QLQ Cancer Module (BR23) analysis was not performed.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sunitinib</title>
          <description>37.5 mg daily, continuous dosing</description>
        </group>
        <group group_id="E2">
          <title>Capecitabine</title>
          <description>1250 milligrams per square meter (mg/m^2) or 1000 mg/m^2 in older participants, twice daily for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Haematotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Diarrhoea haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Gastrointestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Fungal peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Peritonitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Postoperative respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="228" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="229" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Anisocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Intracardiac thrombus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Ear haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Thyroiditis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Eye discharge</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Eye swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Eyelid ptosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Ocular surface disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Periorbital oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Pupils unequal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Scleral pigmentation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Scotoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Xerophthalmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Abdominal rigidity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Abdominal tenderness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Anal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Anorectal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Duodenogastric reflux</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Gastrointestinal motility disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Gingival disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Gingival hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Gingival swelling</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Glossitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Glossodynia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Lip discolouration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Lip disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Mouth haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Oesophageal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Oesophageal spasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Oral discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Painful defaecation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Periodontal disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Pneumoperitoneum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Reflux oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Salivary hypersecretion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Tongue ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Tooth discolouration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Administration site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Axillary pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Extravasation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Localised oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Mucosal dryness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Nodule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Sensation of foreign body</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Xerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hepatic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hepatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Iodine allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Amoebiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Breast infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Dacryocystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Nail infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Vulvovaginitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Ligament injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Nail injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Open wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Wound complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Wound secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Blood albumin decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Blood cholesterol decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Blood thyroid stimulating hormone decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Blood thyroid stimulating hormone increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Breath sounds abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Haemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Heart sounds abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Leucine aminopeptidase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Protein total decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Prothrombin time shortened</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Pulmonary physical examination abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Thyroxine increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Tri-iodothyronine free increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>White blood cell count</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hypophagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Lactose intolerance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Polydipsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Bone fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Limb discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Osteonecrosis of jaw</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Sensation of heaviness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Tendon pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Torticollis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Trismus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ageusia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Carotid arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Cerebellar syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Dysaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hyperaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hyperreflexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Nystagmus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Sensory disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>VIth nerve disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Mood swings</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Chromaturia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Perinephric effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Renal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Urethral disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Atrophic vulvovaginitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Breast disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Breast haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Breast swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Dysfunctional uterine bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Pruritus genital</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Vulvovaginal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Vulvovaginal dryness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Dry throat</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hypoventilation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Increased upper airway secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Nasal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Nasal dryness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Nasal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Nasal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Sputum increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Tachypnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Upper-airway cough syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Dermatitis bullous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Exfoliative rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Haemorrhage subcutaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hair colour changes</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Koilonychia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Madarosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Nail bed inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Nail discolouration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Nail pigmentation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Nail toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Onychoclasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Onycholysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Palmar erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="149" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Pigmentation disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Rash vesicular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Skin discolouration</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Skin fissures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Skin hypopigmentation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Skin mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Skin reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Skin toxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Skin ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Yellow skin</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Skin neoplasm excision</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Pallor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to patient enrollment termination, PFS/OR/TTP/DR were done by investigator assessment due to lack of central review data and TTR/EORTC QLQ-C30/QLQ BR23 analyses were not done. Those enrolled could receive capecitabine or enter an extension trial.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

